What Is Vitreomacular Adhesion? Symptoms & Treatment

Vitreomacular adhesion (VMA) is a condition in which the gel-like substance filling the eye remains stuck to the macula, the central part of the retina responsible for sharp vision, after it has begun to naturally pull away during aging. In most people this attachment causes no symptoms at all and resolves on its own. When the adhesion starts pulling on the macula hard enough to distort its structure, it crosses into a related condition called vitreomacular traction (VMT), which can blur and warp your vision and sometimes requires treatment. Understanding where you fall on that spectrum is the key to knowing what, if anything, needs to happen next.

How the Vitreous Normally Separates From the Retina

The inside of your eye is filled with a clear gel called the vitreous humor. In younger eyes the vitreous is firmly attached to the retina across a broad surface, especially at the macula. As you age, two things happen simultaneously: the gel liquefies and the bond between the vitreous and the retina weakens. Eventually the vitreous peels away from the retina in an event called posterior vitreous detachment, or PVD. This is extremely common and usually finishes without any problems. Most people over 60 or 70 have experienced at least a partial PVD, often without ever noticing it.¹

VMA happens when that separation gets partway done and then stalls. The vitreous has pulled away from most of the retina’s surface but remains attached at or near the fovea, the very center of the macula. Think of a piece of tape peeling off a wall but still stuck in one spot. That residual point of contact is the adhesion.

When Adhesion Becomes Traction

Not every VMA causes trouble. An international classification group defined VMA as a state where the vitreous is still attached to the macula but the fovea’s shape looks entirely normal on imaging. In other words, there is contact but no distortion. Vitreomacular traction, by contrast, is diagnosed when that persistent attachment is warping the macula’s structure, potentially producing small cysts, fluid pockets, or changes in retinal thickness.²

Size matters here. Adhesions are classified as focal (1,500 micrometers or less in diameter) or broad (larger than 1,500 micrometers). Counterintuitively, smaller adhesions tend to cause more trouble, not less. A narrow point of attachment concentrates the pulling force on a tiny area of the fovea, which can produce a small cyst or pit in the retinal tissue. A broader attachment spreads the force out, leading to more subtle flattening rather than a focal tear.³ Classification studies also note morphological differences visible on imaging: some adhesions create a V-shaped or cord-like profile, while others look more like a J- or U-shape, and the shape can influence which retinal layers get disrupted first.⁴

Who Gets It and How Common Is It

Because VMA is essentially a snapshot of an aging process caught mid-stride, it is surprisingly common in older adults. A population-based study in Northern Ireland found VMA in about 23% of people examined, while VMT, the more problematic version, appeared in only about 0.5%.⁵ A separate study of adults over 40 without known macular disease reported VMA or VMT in about 39% and 1%, respectively, and found that for each additional year of age, the odds of still having VMA dropped by about 7%, consistent with the idea that in most people the vitreous eventually finishes detaching.⁶

The upshot is that the vast majority of VMA is incidental, something a retina specialist sees on a scan but that never becomes symptomatic. The small subset that progresses to VMT is the group that needs close monitoring.

Symptoms to Watch For

When VMA is truly asymptomatic, you will not know you have it unless an eye doctor spots it during a routine exam. Once the adhesion transitions to traction and begins distorting the macula, symptoms tend to emerge gradually:

Blurred vision: Central sharpness drops because the pulling changes the macula’s shape, scattering the light that would normally focus there.
Metamorphopsia: Straight lines look wavy or bent. This is probably the most distinctive symptom. Patients with self-reported metamorphopsia scored roughly 9 points lower on a standardized vision-related quality-of-life questionnaire than those without it, an effect that was independent of their measured visual acuity.⁷
Floaters and flashes: These can occur as the vitreous tugs on the retina during eye movements.⁸

None of these symptoms are unique to VMT, so they overlap with other macular conditions like epiretinal membranes or early macular degeneration. The distinguishing step is imaging.

How It Is Diagnosed

Optical coherence tomography (OCT) is the tool that changed everything about understanding and managing VMA. OCT creates a cross-sectional image of the retina at micrometer resolution, letting the doctor see exactly where the vitreous is still attached, how wide the attachment is, and whether the fovea’s layers are being pulled out of shape.⁹ Before OCT became widely available, many of these cases were either missed entirely or only discovered once a macular hole had already formed. Today, serial OCT scans taken every few months let doctors track the angle, diameter, and macular thickness over time, which is central to deciding when to intervene.¹⁰

Does It Resolve on Its Own

A meaningful fraction of VMT cases does resolve without treatment. In one prospective study, about 24% of eyes achieved complete resolution by the last visit. However, roughly 13% progressed to a full-thickness macular hole, and the remaining 63% showed persistent traction without resolution.¹¹ Another study of 46 patients found that spontaneous resolution occurred in a little under half of those followed, most commonly between 6 and 12 months, and that younger age improved the chances of the vitreous releasing on its own.¹²

These numbers underline why many retina specialists start with watchful waiting rather than rushing to treat. If vision is only mildly affected and the macula’s structure is not severely deformed, monitoring with serial OCT every three months or so is a reasonable first step. When traction does not resolve and vision keeps declining, studies suggest patients lose about one letter per year on a standard eye chart.¹² That slow pace gives doctors time to watch before committing to more aggressive measures.

Ocriplasmin Injection

The first non-surgical option for symptomatic VMA and VMT is ocriplasmin, an enzyme injected directly into the eye. It works by breaking down fibronectin and laminin, two proteins that help glue the vitreous to the retina. In pivotal trials, the adhesion resolved in about 27% of eyes treated with ocriplasmin compared to roughly 10% of eyes that received a placebo injection. For eyes that also had a macular hole, nonsurgical closure occurred in about 41% of the ocriplasmin group versus 11% of the placebo group.¹³

Those numbers show the treatment works in a meaningful proportion of patients, but it also means the majority of injected eyes do not see resolution from the drug alone. Ocriplasmin comes with side effects, too. About 5% of patients in clinical trials reported visual impairment (versus about 2% in the placebo arm), and roughly 2% experienced dyschromatopsia, a temporary yellowing of vision linked to changes in how the retina’s photoreceptor cells respond. Electroretinography in affected patients showed decreased signaling, suggesting that the enzyme’s activity was not limited to the vitreoretinal interface and could transiently affect photoreceptors as well, particularly rods more than cones.¹⁴ Cases of more severe and prolonged visual loss have been reported, though they appear to be uncommon.¹⁵

Because of this mixed success-and-risk profile, ocriplasmin tends to be offered to patients with focal adhesions and relatively preserved visual acuity who want to avoid surgery but are not content with watching and waiting.

Pneumatic Vitreolysis

A less widely discussed option is pneumatic vitreolysis, which involves injecting a small gas bubble into the eye. The bubble floats up against the macula and mechanically separates the vitreous from the retinal surface as it expands and then slowly reabsorbs. One study reported an overall success rate of 86% in releasing VMT with this technique.¹⁶ The procedure is performed in the office, avoids the operating room, and sidesteps the enzyme-related side effects of ocriplasmin. The main limitation is that patients need to maintain specific head positioning after the injection so the bubble pushes against the right spot, and the technique works best for focal adhesions without a large macular hole.

Surgery

When observation, ocriplasmin, and gas injection are either not appropriate or have failed, the standard surgical approach is pars plana vitrectomy. The surgeon removes the vitreous gel entirely and peels away the membrane attaching it to the macula. In the largest compiled data, about two-thirds of eyes improved after vitrectomy, roughly a third gained two or more lines on an eye chart, and mean visual acuity improved from about 20/94 before surgery to about 20/53 afterward. Around 9% of eyes lost acuity.¹⁷ Smaller series have reported improvement rates as high as 89%.¹⁸

The most common complications after vitrectomy are cataract progression (about 63% of eyes that still had a natural lens went on to develop cataracts), epiretinal membrane formation in about 6% of eyes, and retinal detachment in about 5%.¹⁷ Cataract formation is almost expected because removing the vitreous accelerates lens clouding, and many surgeons discuss combined cataract-and-vitrectomy surgery upfront. There is also a risk that peeling the attached membrane may convert a partial-thickness traction into a full-thickness macular hole during surgery, requiring additional steps like gas tamponade to seal it.¹⁹

A newer surgical refinement involves peeling the internal limiting membrane around the fovea but leaving a small disc of membrane in place over the fovea itself, a technique sometimes called foveal-sparing ILM peel. The rationale is to release the traction while protecting the delicate foveal photoreceptors from mechanical trauma during the peel.²⁰ Better preoperative acuity and focal (rather than broad) adhesion patterns are associated with better surgical outcomes overall.²¹

The Risk of Macular Hole Formation

The main reason doctors keep a close eye on VMT is the risk that ongoing traction will tear a full-thickness macular hole through the center of the retina. One prospective study found that about 11% of eyes with focal VMT progressed to a macular hole during follow-up. Eyes with a V-shaped, cord-like attachment profile tended to develop changes in the outer retinal layers first, while those with a broader U-shaped attachment showed inner layer disruption first.²² Once a macular hole forms, surgical repair becomes more urgent because the hole will not close on its own in most cases.

How VMA Affects Treatment of Other Eye Diseases

One area that has received growing attention is how the presence of VMA or VMT affects the response to treatment for wet age-related macular degeneration (AMD). Patients with wet AMD who also had VMA or VMT at baseline showed poorer gains in visual acuity and smaller reductions in retinal thickness at one year when treated with anti-VEGF injections, compared to patients whose vitreous had fully detached. The VMA/VMT group also needed more injections over two years.²³ Similar findings have been reported in other studies examining how the vitreomacular interface status at baseline predicts anti-VEGF outcomes.²⁴

The reasons are not entirely settled, but one theory is that persistent vitreous attachment acts as a scaffold that holds inflammatory mediators and growth factors against the retinal surface, reducing how effectively anti-VEGF drugs can circulate and clear them. This means that if you are being treated for wet AMD and your doctor mentions VMA on your OCT, it is worth asking whether the adhesion could be influencing your treatment response.

Living With a Diagnosis of VMA

If you have been told you have VMA, the single most useful thing you can do at home is monitor for metamorphopsia. An Amsler grid, a simple square grid of lines you can print or view on a screen, lets you check for new waviness in your central vision. You hold it at reading distance, cover one eye, and look at the center dot. If any of the lines around it start looking bent or distorted when they previously looked straight, that is a sign the adhesion may be pulling harder on your macula, and it warrants a prompt call to your eye doctor.

Many people diagnosed with VMA go on for years without any progression. The condition is overwhelmingly benign in its early, asymptomatic phase. The challenge is that progression, when it does happen, tends to be gradual enough that you may adapt to the vision changes without fully registering them. Keeping up with scheduled OCT scans, even when your vision seems stable, is the most reliable way to catch a shift from adhesion to traction before it causes lasting damage.